[424B7] Marker Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7)
Marker Therapeutics, Inc. (Nasdaq: MRKR) filed Prospectus Supplement No. 2 to its November 2018 resale registration statement. The sole purpose is to update the 鈥淪elling Stockholders鈥� table after John R. Wilson transferred his holdings to the John R. Wilson Revocable Trust U/A DTD 08/03/2017, for which he is sole trustee. The trust now appears as a substitute selling stockholder.
- Shares affected: 781,200 common shares (post-1:10 reverse split) are beneficially owned; up to 606,078 shares (鈮�0.54 m) are registered for resale; 175,122 shares would remain if the entire allotment is sold.
- Ownership impact: The trust currently controls 1.5 % of MRKR鈥檚 11,314,835 outstanding shares (as of 30 Jun 2025). Percentage falls to ~0.2 % post-sale.
- Capital effects: These are already-issued shares鈥攏o new dilution to existing shareholders. However, resale could increase float and near-term supply.
- Price reference: Last reported price on 4 Aug 2025 was $1.24.
- Governance note: Mr. Wilson, a former director, resigned 24 Jan 2025; disclosure aligns holdings with current status.
All other terms, risk factors and the plan of distribution in the original prospectus remain unchanged.
Marker Therapeutics, Inc. (Nasdaq: MRKR) ha depositato il Supplemento al Prospetto n. 2 relativo alla sua dichiarazione di registrazione per la rivendita di novembre 2018. Lo scopo unico 猫 aggiornare la tabella dei 鈥淪oci Venditori鈥� dopo che John R. Wilson ha trasferito le sue partecipazioni al John R. Wilson Revocable Trust U/A DTD 08/03/2017, di cui 猫 unico fiduciario. Il trust appare ora come socio venditore sostitutivo.
- Azioni interessate: 781.200 azioni ordinarie (post frazionamento inverso 1:10) sono detenute in via beneficiaria; fino a 606.078 azioni (circa 0,54 milioni) sono registrate per la rivendita; 175.122 azioni rimarrebbero in possesso se l鈥檌ntero lotto venisse venduto.
- Impatto sulla propriet脿: Il trust controlla attualmente l鈥�1,5% delle 11.314.835 azioni in circolazione di MRKR (al 30 giugno 2025). La percentuale scende a circa lo 0,2% dopo la vendita.
- Effetti sul capitale: Si tratta di azioni gi脿 emesse, quindi nessuna nuova diluizione per gli azionisti esistenti. Tuttavia, la rivendita potrebbe aumentare il flottante e l鈥檕fferta a breve termine.
- Riferimento di prezzo: L鈥檜ltimo prezzo riportato al 4 agosto 2025 era di 1,24 $.
- Nota sulla governance: Il signor Wilson, ex amministratore, si 猫 dimesso il 24 gennaio 2025; la comunicazione aggiorna le partecipazioni allo stato attuale.
Tutti gli altri termini, i fattori di rischio e il piano di distribuzione riportati nel prospetto originale rimangono invariati.
Marker Therapeutics, Inc. (Nasdaq: MRKR) present贸 el Suplemento al Prospecto N潞 2 de su declaraci贸n de registro de reventa de noviembre de 2018. El 煤nico prop贸sito es actualizar la tabla de 鈥淎ccionistas Vendedores鈥� tras la transferencia de sus participaciones por parte de John R. Wilson al John R. Wilson Revocable Trust U/A DTD 08/03/2017, del cual es 煤nico fiduciario. El fideicomiso ahora aparece como accionista vendedor sustituto.
- Acciones afectadas: 781,200 acciones ordinarias (post-split inverso 1:10) son propiedad beneficiaria; hasta 606,078 acciones (鈮�0.54 millones) est谩n registradas para reventa; quedar铆an 175,122 acciones si se vende la totalidad del lote.
- Impacto en la propiedad: El fideicomiso controla actualmente el 1.5 % de las 11,314,835 acciones en circulaci贸n de MRKR (al 30 de junio de 2025). El porcentaje cae a ~0.2 % tras la venta.
- Efectos en el capital: Son acciones ya emitidas, sin diluci贸n nueva para los accionistas actuales. Sin embargo, la reventa podr铆a aumentar el flotante y la oferta a corto plazo.
- Referencia de precio: El 煤ltimo precio reportado el 4 de agosto de 2025 fue de $1.24.
- Nota de gobierno corporativo: El Sr. Wilson, exdirector, renunci贸 el 24 de enero de 2025; la divulgaci贸n actualiza la tenencia acorde al estado actual.
Todos los dem谩s t茅rminos, factores de riesgo y el plan de distribuci贸n del prospecto original permanecen sin cambios.
Marker Therapeutics, Inc. (雮橃姢雼�: MRKR)電� 2018雲� 11鞗� 鞛寪毵� 霌彪 鞁犾箔靹滌棎 雽�頃� 氤挫订 靹る獏靹� 2順鸽ゼ 鞝滌稖頄堨姷雼堧嫟. 鞙犾澕頃� 氇╈爜鞚� John R. Wilson鞚� 鞛愳嫚鞚� 氤挫湢 欤检嫕鞚� John R. Wilson Revocable Trust U/A DTD 08/03/2017搿� 鞚挫爠頃� 頉� 鈥橅寪毵� 欤检＜鈥� 響滊ゼ 鞐呺嵃鞚错姼頃橂姅 瓴冹瀰雼堧嫟. 攴鸽姅 頃措嫻 鞁犿儊鞚� 雼弲 靾橅儊鞛愳瀰雼堧嫟. 鞁犿儊鞚� 雽�觳� 韺愲Г 欤检＜搿� 霌膘灛霅橃棃鞀惦媹雼�.
- 鞓來枼鞚� 氚涬姅 欤检嫕: 781,200 氤错喌欤�(1:10 鞎‰┐氤戫暕 頉�)臧� 鞁れ 靻岇湢霅橃棃鞙茧┌, 斓滊寑 606,078欤�(鞎� 54毵� 欤�)臧� 鞛寪毵� 霌彪霅橃柎 鞛堨姷雼堧嫟. 鞝勳泊 氚办爼鞚� 韺愲Г霅� 瓴届毎 175,122欤缄皜 雮矊 霅╇媹雼�.
- 靻岇湢甓� 鞓來枼: 鞁犿儊鞚� 順勳灛 MRKR鞚� 11,314,835欤�(2025雲� 6鞗� 30鞚� 旮办)鞚� 1.5%毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 韺愲Г 頉� 牍勳湪鞚� 鞎� 0.2%搿� 臧愳唽頃╇媹雼�.
- 鞛愲掣 鞓來枼: 鞚措姅 鞚措 氚滍枆霅� 欤检嫕鞙茧 旮办〈 欤检＜鞐� 雽�頃� 頋劃 須臣電� 鞐嗢姷雼堧嫟. 雼る, 鞛寪毵る姅 鞙犿喌 欤检嫕 靾橃檧 雼赴 瓿店笁鞚� 歃濌皜鞁滍偓 靾� 鞛堨姷雼堧嫟.
- 臧�瓴� 彀戈碃: 2025雲� 8鞗� 4鞚� 毵堨毵� 氤搓碃 臧�瓴╈潃 $1.24鞓�鞀惦媹雼�.
- 瓯半矂雱岇姢 彀戈碃: 鞝� 鞚挫偓鞚� 鞙岇姩 鞌姅 2025雲� 1鞗� 24鞚� 靷瀯頄堨溂氅�, 鞚措矆 瓿奠嫓電� 氤挫湢 順勴櫓鞚� 順勳灛 靸來儨鞐� 毵炾矊 臁办爼頃� 瓴冹瀰雼堧嫟.
旮绊儉 氇摖 臁瓣贝, 鞙勴棙 鞖旍澑 氚� 氚绊彫 瓿勴殟鞚� 鞗愲灅鞚� 靹る獏靹滌檧 霃欖澕頃橁矊 鞙犾霅╇媹雼�.
Marker Therapeutics, Inc. (Nasdaq : MRKR) a d茅pos茅 le Suppl茅ment au Prospectus n掳 2 relatif 脿 sa d茅claration d'enregistrement de revente de novembre 2018. L'unique objectif est de mettre 脿 jour le tableau des 芦 Actionnaires vendeurs 禄 apr猫s que John R. Wilson ait transf茅r茅 ses participations au John R. Wilson Revocable Trust U/A DTD 08/03/2017, dont il est le seul fiduciaire. Le trust appara卯t d茅sormais comme actionnaire vendeur de substitution.
- Actions concern茅es : 781 200 actions ordinaires (apr猫s regroupement invers茅 1:10) sont d茅tenues 脿 titre b茅n茅ficiaire ; jusqu'脿 606 078 actions (鈮�0,54 M) sont enregistr茅es pour la revente ; 175 122 actions resteraient si l'int茅gralit茅 de l'allocation est vendue.
- Impact sur la propri茅t茅 : Le trust contr么le actuellement 1,5 % des 11 314 835 actions en circulation de MRKR (au 30 juin 2025). Le pourcentage tombe 脿 ~0,2 % apr猫s la vente.
- Effets sur le capital : Il s'agit d'actions d茅j脿 茅mises 鈥� aucune dilution nouvelle pour les actionnaires existants. Toutefois, la revente pourrait augmenter le flottant et l'offre 脿 court terme.
- R茅f茅rence de prix : Le dernier cours rapport茅 au 4 ao没t 2025 茅tait de 1,24 $.
- Note sur la gouvernance : M. Wilson, ancien administrateur, a d茅missionn茅 le 24 janvier 2025 ; la divulgation aligne les participations sur la situation actuelle.
Les autres termes, facteurs de risque et le plan de distribution du prospectus original restent inchang茅s.
Marker Therapeutics, Inc. (Nasdaq: MRKR) hat den Nachtrag Nr. 2 zu seiner Verkaufsregistrierungserkl盲rung vom November 2018 eingereicht. Der alleinige Zweck besteht darin, die Tabelle der 鈥濾erk盲uferaktion盲re鈥� zu aktualisieren, nachdem John R. Wilson seine Anteile auf den John R. Wilson Revocable Trust U/A DTD 08/03/2017 眉bertragen hat, bei dem er alleiniger Treuh盲nder ist. Der Trust erscheint nun als ersetzender Verk盲uferaktion盲r.
- Betroffene Aktien: 781.200 Stammaktien (nach 1:10 Reverse Split) werden wirtschaftlich gehalten; bis zu 606.078 Aktien (鈮�0,54 Mio.) sind f眉r den Wiederverkauf registriert; 175.122 Aktien blieben, falls die gesamte Zuteilung verkauft wird.
- Eigentumsauswirkung: Der Trust kontrolliert derzeit 1,5 % von MRKR鈥檚 11.314.835 ausstehenden Aktien (Stand 30. Juni 2025). Der Anteil sinkt auf ~0,2 % nach dem Verkauf.
- Kapitalwirkung: Es handelt sich um bereits ausgegebene Aktien 鈥� keine neue Verw盲sserung f眉r bestehende Aktion盲re. Die Wiederver盲u脽erung k枚nnte jedoch den Streubesitz und das kurzfristige Angebot erh枚hen.
- Preisreferenz: Der zuletzt gemeldete Kurs am 4. August 2025 betrug 1,24 $.
- Governance-Hinweis: Herr Wilson, ein ehemaliges Vorstandsmitglied, trat am 24. Januar 2025 zur眉ck; die Offenlegung gleicht die Beteiligungen dem aktuellen Status an.
Alle anderen Bedingungen, Risikofaktoren und der Vertriebsplan im Originalprospekt bleiben unver盲ndert.
- Improved transparency by accurately naming the Wilson Revocable Trust and reflecting post-split share counts.
- No dilution because shares were previously issued; capital structure unchanged.
- Potential supply overhang: up to 606,078 shares (1.5 % of OS) may enter the market, pressuring the share price.
- Former director selling could be perceived negatively by investors monitoring insider sentiment.
Insights
TL;DR: Filing registers 606 k shares for resale; no dilution but adds float and possible overhang.
The amendment simply substitutes the Wilson Revocable Trust for the individual, aligning the ownership table with a prior November 2021 transfer and the January 2023 1-for-10 reverse split. Because the shares are outstanding, MRKR receives no proceeds. Still, 606,078 shares鈥攁bout 5.4 % of total daily volume if we assume 1 0 m average shares pre-split鈥攃ould pressure the $1.24 stock if placed quickly. Post-sale ownership of 0.2 % is immaterial. From a credit or cash-flow standpoint, impact is neutral; from a technical standpoint, modestly negative due to increased supply.
TL;DR: Routine housekeeping improves disclosure accuracy; governance risk minimal.
The update ensures compliance with Rule 424(b)(7) by naming the correct registrant of record after an estate-planning transfer. Notably, the seller is a former director; clear disclosure avoids conflict-of-interest issues and signals sound governance practice. There are no new warrants, inducements, or related-party transactions disclosed. Overall impact on shareholder rights and board dynamics is negligible.
Marker Therapeutics, Inc. (Nasdaq: MRKR) ha depositato il Supplemento al Prospetto n. 2 relativo alla sua dichiarazione di registrazione per la rivendita di novembre 2018. Lo scopo unico 猫 aggiornare la tabella dei 鈥淪oci Venditori鈥� dopo che John R. Wilson ha trasferito le sue partecipazioni al John R. Wilson Revocable Trust U/A DTD 08/03/2017, di cui 猫 unico fiduciario. Il trust appare ora come socio venditore sostitutivo.
- Azioni interessate: 781.200 azioni ordinarie (post frazionamento inverso 1:10) sono detenute in via beneficiaria; fino a 606.078 azioni (circa 0,54 milioni) sono registrate per la rivendita; 175.122 azioni rimarrebbero in possesso se l鈥檌ntero lotto venisse venduto.
- Impatto sulla propriet脿: Il trust controlla attualmente l鈥�1,5% delle 11.314.835 azioni in circolazione di MRKR (al 30 giugno 2025). La percentuale scende a circa lo 0,2% dopo la vendita.
- Effetti sul capitale: Si tratta di azioni gi脿 emesse, quindi nessuna nuova diluizione per gli azionisti esistenti. Tuttavia, la rivendita potrebbe aumentare il flottante e l鈥檕fferta a breve termine.
- Riferimento di prezzo: L鈥檜ltimo prezzo riportato al 4 agosto 2025 era di 1,24 $.
- Nota sulla governance: Il signor Wilson, ex amministratore, si 猫 dimesso il 24 gennaio 2025; la comunicazione aggiorna le partecipazioni allo stato attuale.
Tutti gli altri termini, i fattori di rischio e il piano di distribuzione riportati nel prospetto originale rimangono invariati.
Marker Therapeutics, Inc. (Nasdaq: MRKR) present贸 el Suplemento al Prospecto N潞 2 de su declaraci贸n de registro de reventa de noviembre de 2018. El 煤nico prop贸sito es actualizar la tabla de 鈥淎ccionistas Vendedores鈥� tras la transferencia de sus participaciones por parte de John R. Wilson al John R. Wilson Revocable Trust U/A DTD 08/03/2017, del cual es 煤nico fiduciario. El fideicomiso ahora aparece como accionista vendedor sustituto.
- Acciones afectadas: 781,200 acciones ordinarias (post-split inverso 1:10) son propiedad beneficiaria; hasta 606,078 acciones (鈮�0.54 millones) est谩n registradas para reventa; quedar铆an 175,122 acciones si se vende la totalidad del lote.
- Impacto en la propiedad: El fideicomiso controla actualmente el 1.5 % de las 11,314,835 acciones en circulaci贸n de MRKR (al 30 de junio de 2025). El porcentaje cae a ~0.2 % tras la venta.
- Efectos en el capital: Son acciones ya emitidas, sin diluci贸n nueva para los accionistas actuales. Sin embargo, la reventa podr铆a aumentar el flotante y la oferta a corto plazo.
- Referencia de precio: El 煤ltimo precio reportado el 4 de agosto de 2025 fue de $1.24.
- Nota de gobierno corporativo: El Sr. Wilson, exdirector, renunci贸 el 24 de enero de 2025; la divulgaci贸n actualiza la tenencia acorde al estado actual.
Todos los dem谩s t茅rminos, factores de riesgo y el plan de distribuci贸n del prospecto original permanecen sin cambios.
Marker Therapeutics, Inc. (雮橃姢雼�: MRKR)電� 2018雲� 11鞗� 鞛寪毵� 霌彪 鞁犾箔靹滌棎 雽�頃� 氤挫订 靹る獏靹� 2順鸽ゼ 鞝滌稖頄堨姷雼堧嫟. 鞙犾澕頃� 氇╈爜鞚� John R. Wilson鞚� 鞛愳嫚鞚� 氤挫湢 欤检嫕鞚� John R. Wilson Revocable Trust U/A DTD 08/03/2017搿� 鞚挫爠頃� 頉� 鈥橅寪毵� 欤检＜鈥� 響滊ゼ 鞐呺嵃鞚错姼頃橂姅 瓴冹瀰雼堧嫟. 攴鸽姅 頃措嫻 鞁犿儊鞚� 雼弲 靾橅儊鞛愳瀰雼堧嫟. 鞁犿儊鞚� 雽�觳� 韺愲Г 欤检＜搿� 霌膘灛霅橃棃鞀惦媹雼�.
- 鞓來枼鞚� 氚涬姅 欤检嫕: 781,200 氤错喌欤�(1:10 鞎‰┐氤戫暕 頉�)臧� 鞁れ 靻岇湢霅橃棃鞙茧┌, 斓滊寑 606,078欤�(鞎� 54毵� 欤�)臧� 鞛寪毵� 霌彪霅橃柎 鞛堨姷雼堧嫟. 鞝勳泊 氚办爼鞚� 韺愲Г霅� 瓴届毎 175,122欤缄皜 雮矊 霅╇媹雼�.
- 靻岇湢甓� 鞓來枼: 鞁犿儊鞚� 順勳灛 MRKR鞚� 11,314,835欤�(2025雲� 6鞗� 30鞚� 旮办)鞚� 1.5%毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 韺愲Г 頉� 牍勳湪鞚� 鞎� 0.2%搿� 臧愳唽頃╇媹雼�.
- 鞛愲掣 鞓來枼: 鞚措姅 鞚措 氚滍枆霅� 欤检嫕鞙茧 旮办〈 欤检＜鞐� 雽�頃� 頋劃 須臣電� 鞐嗢姷雼堧嫟. 雼る, 鞛寪毵る姅 鞙犿喌 欤检嫕 靾橃檧 雼赴 瓿店笁鞚� 歃濌皜鞁滍偓 靾� 鞛堨姷雼堧嫟.
- 臧�瓴� 彀戈碃: 2025雲� 8鞗� 4鞚� 毵堨毵� 氤搓碃 臧�瓴╈潃 $1.24鞓�鞀惦媹雼�.
- 瓯半矂雱岇姢 彀戈碃: 鞝� 鞚挫偓鞚� 鞙岇姩 鞌姅 2025雲� 1鞗� 24鞚� 靷瀯頄堨溂氅�, 鞚措矆 瓿奠嫓電� 氤挫湢 順勴櫓鞚� 順勳灛 靸來儨鞐� 毵炾矊 臁办爼頃� 瓴冹瀰雼堧嫟.
旮绊儉 氇摖 臁瓣贝, 鞙勴棙 鞖旍澑 氚� 氚绊彫 瓿勴殟鞚� 鞗愲灅鞚� 靹る獏靹滌檧 霃欖澕頃橁矊 鞙犾霅╇媹雼�.
Marker Therapeutics, Inc. (Nasdaq : MRKR) a d茅pos茅 le Suppl茅ment au Prospectus n掳 2 relatif 脿 sa d茅claration d'enregistrement de revente de novembre 2018. L'unique objectif est de mettre 脿 jour le tableau des 芦 Actionnaires vendeurs 禄 apr猫s que John R. Wilson ait transf茅r茅 ses participations au John R. Wilson Revocable Trust U/A DTD 08/03/2017, dont il est le seul fiduciaire. Le trust appara卯t d茅sormais comme actionnaire vendeur de substitution.
- Actions concern茅es : 781 200 actions ordinaires (apr猫s regroupement invers茅 1:10) sont d茅tenues 脿 titre b茅n茅ficiaire ; jusqu'脿 606 078 actions (鈮�0,54 M) sont enregistr茅es pour la revente ; 175 122 actions resteraient si l'int茅gralit茅 de l'allocation est vendue.
- Impact sur la propri茅t茅 : Le trust contr么le actuellement 1,5 % des 11 314 835 actions en circulation de MRKR (au 30 juin 2025). Le pourcentage tombe 脿 ~0,2 % apr猫s la vente.
- Effets sur le capital : Il s'agit d'actions d茅j脿 茅mises 鈥� aucune dilution nouvelle pour les actionnaires existants. Toutefois, la revente pourrait augmenter le flottant et l'offre 脿 court terme.
- R茅f茅rence de prix : Le dernier cours rapport茅 au 4 ao没t 2025 茅tait de 1,24 $.
- Note sur la gouvernance : M. Wilson, ancien administrateur, a d茅missionn茅 le 24 janvier 2025 ; la divulgation aligne les participations sur la situation actuelle.
Les autres termes, facteurs de risque et le plan de distribution du prospectus original restent inchang茅s.
Marker Therapeutics, Inc. (Nasdaq: MRKR) hat den Nachtrag Nr. 2 zu seiner Verkaufsregistrierungserkl盲rung vom November 2018 eingereicht. Der alleinige Zweck besteht darin, die Tabelle der 鈥濾erk盲uferaktion盲re鈥� zu aktualisieren, nachdem John R. Wilson seine Anteile auf den John R. Wilson Revocable Trust U/A DTD 08/03/2017 眉bertragen hat, bei dem er alleiniger Treuh盲nder ist. Der Trust erscheint nun als ersetzender Verk盲uferaktion盲r.
- Betroffene Aktien: 781.200 Stammaktien (nach 1:10 Reverse Split) werden wirtschaftlich gehalten; bis zu 606.078 Aktien (鈮�0,54 Mio.) sind f眉r den Wiederverkauf registriert; 175.122 Aktien blieben, falls die gesamte Zuteilung verkauft wird.
- Eigentumsauswirkung: Der Trust kontrolliert derzeit 1,5 % von MRKR鈥檚 11.314.835 ausstehenden Aktien (Stand 30. Juni 2025). Der Anteil sinkt auf ~0,2 % nach dem Verkauf.
- Kapitalwirkung: Es handelt sich um bereits ausgegebene Aktien 鈥� keine neue Verw盲sserung f眉r bestehende Aktion盲re. Die Wiederver盲u脽erung k枚nnte jedoch den Streubesitz und das kurzfristige Angebot erh枚hen.
- Preisreferenz: Der zuletzt gemeldete Kurs am 4. August 2025 betrug 1,24 $.
- Governance-Hinweis: Herr Wilson, ein ehemaliges Vorstandsmitglied, trat am 24. Januar 2025 zur眉ck; die Offenlegung gleicht die Beteiligungen dem aktuellen Status an.
Alle anderen Bedingungen, Risikofaktoren und der Vertriebsplan im Originalprospekt bleiben unver盲ndert.
Filed pursuant to Rule 424(b)(7)
Registration No. 333-228059
PROSPECTUS SUPPLEMENT NO. 2
(To prospectus dated November 16, 2018, and
Prospectus Supplement No. 1 dated January 29, 2019)
This Prospectus Supplement No. 2 supplements the prospectus dated November 16, 2018, as supplemented by Prospectus Supplement No. 1 dated January 29, 2019, included in a registration statement that we filed with the SEC (together the “Prospectus”) covering the registering for resale by the selling stockholders named in the Prospectus of up to 3,141,425 shares of our common stock described in the Prospectus.
The purpose of this Prospectus Supplement No. 2 is solely to supplement and amend the “Selling Stockholders” section commencing on page 11 of the Prospectus to reflect in the Selling Stockholder table a transfer from a selling stockholder previously identified in the Prospectus to another entity which as a result of such transfer is being substituted as a selling stockholder.
This prospectus supplement is not complete without, and may not be utilized except in connection with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement is qualified by reference to the Prospectus, except to the extent that the information provided by this prospectus supplement supersedes information contained in the Prospectus. Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the prospectus.
Our common stock is quoted on the Nasdaq Capital Market under the symbol “MRKR.” On August 4, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $1.24 per share. You are urged to obtain current market quotations for the common stock.
Investing in our securities involves risks. You should review carefully the risks and uncertainties described under the heading “Risk Factors” beginning on page 6 of the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is August 5, 2025.
SELLING STOCKHOLDERS
The information in the table appearing under the caption “Selling Stockholders” commencing on page 11 of the Prospectus is hereby supplemented and amended by adding the information below with respect to a selling stockholder not previously listed in the Prospectus, and by superseding the information with respect to the selling stockholder identified below that was previously listed in the Prospectus with the information below and reflective of our 1 for 10 reverse stock split effective on January 26, 2023.
The information set forth in the table below has been updated solely to substitute a selling stockholder as a result of a transfer from a selling stockholder previously identified in the Prospectus which transfer is further described in the footnote. The Prospectus selling stockholders table is superseded in part by this Prospectus Supplement No. 2 with the information provided in the table below and with respect to footnote (29) for selling stockholder, John R. Wilson which is replaced with footnote (3) below. The information below with respect to the transfer is based on information provided to us by or on behalf of the selling stockholder listed below on or before August 4, 2025 and we have not independently verified this information.
| Name of Selling Stockholder | Number of Owned | Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus | Number of Shares of Common Stock Beneficially Owned After Offering (2) | Percentage of Shares of Common Stock Beneficially Owned After the Offering (1) (2) | ||||||||||||
| JOHN R WILSON TTEE JOHN R WILSON REVOCABLE TRUST U/A DTD 08/03/2017 (3) | 781,200 | 606,078 | 175,122 | 1.5 | % | |||||||||||
(1) Beneficial ownership is determined in accordance with SEC rules. As of June 30, 2025, there were 11,314,835 shares of our common stock issued and outstanding. Beneficial ownership includes any shares as to which the Selling Stockholder has sole or shared voting power or investment power, and also any shares which the Selling Stockholder has the right to acquire within 60 days of the date hereof, whether through the exercise or conversion of any stock option, convertible security, warrant or other right. The indication herein that shares are beneficially owned is not an admission on the part of the Selling Stockholder that he, she or it is a direct or indirect beneficial owner of those shares.
(2) Assumes the sale by the Selling Stockholder of 100% of the Shares held and able to be sold in offerings made from time to time by the Selling Stockholder pursuant to the Prospectus as supplemented by this Prospectus Supplement. For more information regarding the sale of the Shares by the Selling Stockholders, please see “Plan of Distribution” in the Prospectus to which this Prospectus Supplement relates.
(3) Shares beneficially owned consist of (i) 606,078 shares of common stock acquired by Mr. Wilson in the 2018 Marker Transaction and previously included in footnote (29) of the Prospectus as held directly by Mr. Wilson, (ii) 171,428 shares acquired by Mr. Wilson in a registered public offering by the Company, and (iii) an aggregate of 3,694 shares awarded to Mr. Wilson as part of the Company’s director compensation plan and registered pursuant to Forms S-8 registration statements. On November 30, 2021, Mr. Wilson transferred his shares of common stock in the Company to the John R Wilson Revocable Trust U/A DTD 08/03/2017, for which Mr. Wilson serves as sole Trustee. Mr. Wilson previously served as a member of our Board of Directors and resigned on January 24, 2025.
Source:
FAQ
How many MRKR shares are being registered for resale in this supplement?
Will Marker Therapeutics issue new shares as part of this filing?
What percentage of Marker Therapeutics' stock does the selling stockholder own?
Why was the selling stockholder table updated?
What was MRKR's last reported share price?
